FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
FDA批准摘要：Alpelisib联合Fulvestrant用于治疗HR阳性、HER2阴性、PIK3CA突变的晚期或转移性乳腺癌患者
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-20-3652
Narayan, Preeti; Prowell, Tatiana M; Gao, Jennifer J; Fernandes, Laura L; Li, Emily; Jiang, Xiling; Qiu, Junshan; Fan, Jianghong; Song, Pengfei; Yu, Jingyu; Zhang, Xinyuan; King-Kallimanis, Bellinda L; Chen, Wei; Ricks, Tiffany K; Gong, Yutao; Wang, Xing; Windsor, Katherine; Rhieu, Steve Y; Geiser, Gerlie; Banerjee, Anamitro; Chen, Xiaohong; Reyes Turcu, Francisca; Chatterjee, Deb K; Pathak, Anand; Seidman, Jeffrey; Ghosh, Soma; Philip, Reena; Goldberg, Kirsten B; Kluetz, Paul G; Tang, Shenghui; Amiri-Kordestani, Laleh; Theoret, Marc R; Pazdur, Richard; Beaver, Julia A
